The metabolic effects of a one hour intravenous infusion of the \ g=b\ -2\ x =r eq-\ receptor stimulating drug ritodrine were studied in seven normal pregnant women, three White class A pregnant diabetics and eight White class B-D pregnant diabetics.
concentrations. Plasma glucagon and cortisol concentrations were not influenced by ritodrine. The results suggest that the diabetogenic changes induced by ritodrine are augmented with the severity of diabetes but not ascribable to a diabetes-like change in the function of the endocrine pancreas.
Ritodrine (p-hydroxy-phenylethyl-p-hydroxy-norepinephrine) is a /í-2-receptor stimulating drug widely used in obstetrics for its ability to stop labour and prevent premature parturition.
-mimetic drugs influence metabolism of carbohydrates, lipids and electro¬ lytes. These drugs exert a diabetogenic effect despite a simultaneous increase in the release of insulin (Lunell et al. 1977 ; Thomas et al. 1977; Goldberg et al. 1975 ; Kauppila et al. 1978; Massaro et al. 1977; Fredholm et al. 1978) . The role of glucagon in this context has only been sparsely investigated and results are conflicting (Gerich et al. 1974; Benson et al. 1977; Lipshitz Sc Vinik 1978; Spellacy et al. 1978) .
The aim of the present study was to elucidate further the metabolic actions of ritodrine on pregnant normal and diabetic women classified according to White (1965) . To accomplish this, parameters of carbohydrate and lipid meta¬ bolism as well as plasma concentrations of the pancreatic glucoregulatory hormones, insulin and glucagon have been studied in normal and diabetic latepregnant women subjected to intravenous infusion of ritodrine.
MATERIAL AND METHODS

Subjects
Eighteen pregnant women were included in the study. They were divided into three groups. The first group consisted of seven normal, non-potential diabetic women with¬ out glucosuria and without any medication. The second group consisted of three diabetic women belonging to White class A and the third group of eight diabetic women belonging to White class B-D. White class A patients were treated with diet only, whereas the White class B-D patients were treated with diet and combined inter¬ mediate and fast-acting insulin given twice a day, according to Pedersen (1977 0.14 ± 0.02
1.04 ± 0.07 (Fig. 1) (Fig. 1) (Fig. 2) . The changes did not differ significantly between the groups.
Blood lactate showed a steady rise during and after termination of the in¬ fusion (Fig. 2) (Fig. 2) .
Mean changes in plasma insulin and C-peptide concentrations are shown in Fig. 3 . In normals and White class A patients maximal concentrations were reached at 60 min. Mean increases were 22 ± 6 //IU/ml insulin and 0.65 ± 0.20 pmol/ml C-peptide in normals and 33 ± 14 /dU/ml insulin and 0.75 ± 0.20 pmol/ml C-peptide in White class A patients. Blood Fig. 4 . Potassium decreased at 120 min by 0.5 ± 0.05 (normals), 0.7 ± 0.20 (White class A) and 0.5 ± 0.06 mmol/1 (White class B-D). There was no detectable alteration in the sodium concentration in plasma.
Total plasma cortisol was not influenced by ritodrine infusion.
DISCUSSION
Intravenous infusion of ritodrine elicited an increase in plasma glucose, FFA, /^-hydroxybutyrate and blood lactate and a decrease in standard bicarbonate and plasma potassium. Omitting the insulin treated diabetics, plasma insulin and C-peptide also increased during the infusion. Glucagon and cortisol con¬ centrations were not affected in any of the three groups.
Plasma glucose could be expected to increase (Fig. 1) as /i-mimetic drugs activate liver adenylate cyclase and thus increase the concentration of cyclic AMP in the cells (Exton et al. 1971) . Cyclic AMP glycogen phosphorylase by protein kinase with a resulting glycogenolysis and glucose production (Sutherland Sc Rail 1960; Posner et al. 1962 Posner et al. , 1965 .
Plasma FFA increased during ritodrine infusion in all subjects (Fig. 1 ). This can be explained by the increased level of cyclic AMP causing activation of triglycéride lipase thus increasing the concentration of FFA in plasma (Corbin et al. 1970) .
The ketonaemia (Fig. 2) is presumably a sequel of the elevated plasma levels of FFA which will lead to an increased metabolism of these compounds.
The production of lactate following ritodrine treatment (Fig. 2) (Bihler et al. 1978 ) thereby enhancing glycolysis.
The decrease in standard bicarbonate (Fig. 2) reflects the increased produc¬ tion of ketone bodies and lactic acid.
In the present study all subjects exhibited a fall in plasma potassium (Fig. 4) . The finding that catecholamines enhance the cellular uptake of potassium (Klein et al. 1960) due to stimulation of ß-2-receptors (Wang 8c Clausen 1976) may explain this observation.
Normal subjects and patients belonging to White class A had increases in C-peptide and insulin after ritodrine infusion that were approximately twice as high as expected from the glycaemic stimulus (Faber et al. 1979) (Fig. 3) . This effect is probably due to a direct action of a /j-mimetic drug on insulin secretion (Porte 1967) .
The concentration of glucagon in plasma has been demonstrated to rise after stimulation of /j-receptors (Gerich et al. 1974 (Gerich et al. , 1976 . The authors qouted did not discern between ß-l-and /î-2-receptors. Kaneto et al. (1975) suggestive but did not reach significance with the number of persons examined. A possible explanation for the weaker diabetogenic action of ritodrine in nor¬ mals might be the four-fold increase in plasma insulin in those subjects. Fredholm et al. (1978) found essentially the same differences between normal and diabetic pregnant women during /^-stimulation with salbutamol except for lactate which was found to increase to the same degree in both groups. This difference might be explained by decreased gluconeogenesis from lactate in the liver caused by insulin in our patients (Mortimore 1963; Jefferson et al. 1968 ).
In conclusion, the metabolic changes caused by the infusion of ritodrine were aggravated with the severity of diabetes. The diabetogenic effect of ritodrine could not be explained by inhibition of insulin secretion or stimulation of glucagon secretion or both. The drug seems to exert a direct cellular effect which is augmented with the severity of diabetes. Treatment with iv ritodrine should be performed under close surveillance of plasma glucose, standard bicarbonate and plasma potassium, especially in diabetics.
